Association of tenofovir disoproxil fumarate with primary allograft survival in <scp>HIV</scp>‐positive kidney transplant recipients

Boyle, Suzanne M.; Malat, Gregory; Harhay, Meera N.; Lee, Dong Hoon; Pang, Lisa Y.; Talluri, Sindhura; Sharma, Akshay; Bias, Tiffany; Ranganna, Karthik; Doyle, Alden

doi:10.1111/tid.12727

Cited by 7 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a large single-centre study of HIV+ KT recipients conducted by Boyle et al [45], treatment with TDF at the time of transplant was not associated with 36-month death-censored primary allograft loss after adjustment for DGF and a propensity score for TDF exposure.…”

Section: Discussionmentioning

confidence: 99%

Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

BackgroundKidney transplantation is now a viable alternative to dialysis in HIV-positive patients who achieve good immunovirological control with the currently available antiretroviral therapy regimens. This systematic review and meta-analysis investigate the published evidence of outcome and risk of kidney transplantation in HIV-positive patients following the PRISMA guidelines.MethodsSearches of PubMed, the Cochrane Library and EMBASE identified 27 cohort studies and 1670 case series evaluating the survival of HIV-positive kidney transplant patients published between July 2003 and May 2018. The regimens for induction, maintenance therapy and highly active antiretroviral therapy, acute rejection, patient and graft survival, CD4 count and infectious complications were recorded. We evaluated the patient survival and graft survival at 1 and 3 years respectively, acute rejection rate and also other infectious complications by using a random-effects analysis.ResultsAt 1 year, patient survival was 0.97 (95% CI 0.95; 0.98), graft survival was 0.91 (95% CI 0.88; 0.94), acute rejection was 0.33 (95% CI 0.28; 0.38), and infectious complications was 0.41 (95% CI 0.34; 0.50), and at 3 years, patient survival was 0.94 (95% CI 0.90; 0.97) and graft survival was 0.81 (95% CI 0.74; 0.87).ConclusionsWith careful selection and evaluation, kidney transplantation can be performed with good outcomes in HIV-positive patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For many, this means a tenofovircontaining regimen. Although tenofovir can be nephrotoxic, one small study (24) did not find a difference in posttransplant graft survival on the basis of tenofovir use; however, the rate of graft loss at 3 years was high in both cohorts. More recently, a less nephrotoxic version of tenofovir, tenofovir alafenamide, became available and this is the preferred agent for use in this population.…”

Section: Virologic Monitoring and Controlmentioning

confidence: 92%

Kidney Transplantation in Patients with HIV

Sawinski

2020

Kidney360

View full text Add to dashboard Cite

Individuals with HIV are at increased risk for ESKD. Kidney transplantation is the best treatment for ESKD in the HIV+ population. Despite reduced access to transplantation, patients who are HIV+ have excellent outcomes and clearly benefit from receiving one. Common post-transplant complications and management concerns, including the optimal antiretroviral regimen, immunosuppression protocols, infectious prophylaxis, hepatitis C coinfection, metabolic complications, and malignancy are all discussed.

show abstract

“…Patients who are coinfected with HBV require two drugs with anti-HBV activity, usually a tenofovir-containing regimen. Although tenofovir can be nephrotoxic, one study [25] did not find a difference in post-transplant graft survival in patients on tenofovir. Tenofovir alafenamide, a less toxic version, recently became available and is the preferred agent for use in this population.…”

Section: Viral Coinfection Outcomesmentioning

confidence: 99%

HIV in kidney transplantation

Glicklich

Nog²

2021

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of reviewThe aim of this study was to describe recent developments in renal transplantation for HIV-positive recipients, especially the HIV Organ Policy Equity (HOPE) trial results. Recent findingsHOPE trial data show that HIV-positive Dþ/Rþ results are excellent and similar to DÀ/Rþ in patients controlled on antiretroviral therapy (ART). Patients coinfected with hepatitis C or B virus now have effective treatment available. As pretransplant evaluation and post-transplant management is more complex in HIVpositive individuals early referral is important and coordination of evaluation and care with an infectious disease specialist is critical. HIV coordinated care services should be involved for best outcomes. HIVpositive renal transplant recipients have an increased risk of rejection and evidence suggests that standard lymphocyte depletion induction and maintenance immunosuppression be employed. Cardiovascular risk reduction and surveillance and attention to metabolic bone disease are important for HIV-positive renal transplant recipients. SummaryHIV-positive to HIV-positive renal transplantation has been established as well tolerated and successful. Further efforts are needed to expand access to transplantation in this population.

show abstract

Association of tenofovir disoproxil fumarate with primary allograft survival in HIV‐positive kidney transplant recipients

Cited by 7 publications

References 26 publications

Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis

Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis

Kidney Transplantation in Patients with HIV

HIV in kidney transplantation

Contact Info

Product

Resources

About